Company Overview of AdvanDx, Inc.
AdvanDx, Inc., a diagnostics company, provides molecular diagnostic tests for identification of pathogens causing critical infections in hospitalized patients. The company specializes in molecular testing of positive blood cultures enabling clinical microbiology labs to report pathogen identification results earlier than with conventional testing methods. It offers QuickFISH, a rapid pathogen identification test for potential life threatening bloodstream infections; PNA FISH tests for rapid identification of bacteria and yeast directly from positive blood cultures; and analyte specific reagent PNA probes for ribosomal RNA sequences found in bacteria and fungi. The company also provides PNA F...
Woburn, MA 01801
Founded in 2002
Key Executives for AdvanDx, Inc.
Chairman and Chief Executive Officer
Compensation as of Fiscal Year 2013.
AdvanDx, Inc. Key Developments
AdvanDx Launches Candida QuickFISH
Nov 19 13
AdvanDx announced that it has launched the Candida QuickFISH, a new CE Marked 20-minute rapid diagnostic that can identify up to three Candida species, including C. albicans, C. glabrata, and C. parapsilosis, directly from yeast-positive blood cultures. The nucleic acid–based test enables the microbiologist to report pathogen-identification results 2 to 5 days earlier than conventional methods, aiding clinicians in selecting appropriate antifungal therapy for candidemia patients. QuickFISH Features: QuickFISH is a new, 2nd-generation, molecular-based, rapid diagnostic platform, developed by AdvanDx based on its clinically proven, molecular PNA FISH technology. The new rapid diagnostics enable unprecedented species identification of bacteria and yeast directly from positive blood cultures, allowing pathogen-ID and Gram-stain reporting simultaneously. 5-minute hands-on time: Simplifies laboratory workflow. 20-minute turnaround time: Reported out with Gram-stain results. Built-in, universal controls: Streamlines quality assurance. Minimal instrumentation: Easy start-up.
AdvanDx, Inc. Adds Gram-Negative BC Assay to U.S. and E.U. Commercial Launch of QuickFISH BC
Aug 13 13
AdvanDx, Inc. announcef the commercial launch of Gram-NegativeQuickFISH BC. Gram-Negative QuickFISH BC is a new rapid molecular diagnostic test that identifies potentially life threatening bloodstream infections caused by Escherichia coli, and/orPseudomonas aeruginosa and/orKlebsiella pneumoniae, within 20 minutes of a positive blood culture, making it the fastest method of identifying gram-negative species in positive blood cultures on the market. The new gram-negative assay is immediately available and further expands AdvanDx's QuickFISH Platform that can now identify the pathogens responsible for 90% of positive blood cultures. Today's announcement of the commercial launch of Gram-Negative QuickFISH BC adds to AdvanDx's two gram-positive QuickFISH tests: Staphylococcus QuickFISH BC for the identification of Staphylococcus aureus and/or coagulase-negative staphylococci; and Enterococcus QuickFISH BC, for the identification of Enterococcus faecalis and/or selected other enterococci. AdvanDx anticipates commercial launch of the fourthQuickFISH assay for identification of Candida species from positive blood cultures in the second half of 2013, following regulatory clearance. Gram-negative bloodstream infections, especially those caused by Pseudomonas aeruginosa, are associated with high mortality rates and can be difficult to treat due to increasing resistance to antimicrobial agents. Traditional laboratory testing methods take 24 to 48 hours or longer to identify the causative pathogen, forcing clinicians to treat patients based on limited information. This presents a challenge for the health care provider as the decision to add an anti-pseudomonal drug should ideally be based primarily on knowledge of the infecting species. As a result, patients with gram-negative bloodstream infections are often either subjected to broader than necessary antimicrobial therapies, which may be toxic and may promote the development of drug resistance, or they may be undertreated, increasing their risk for adverse outcomes. QuickFISH is a new, rapid, molecular diagnostic platform developed by AdvanDx based on its clinically- proven, proprietary PNA technology. The new platform enables unprecedented (20 minute) species identification of bacteria directly from positive blood cultures, allowing the reporting of pathogen identification at the same time as the reporting of Gram stain results.
Heiner Dreismann Joins as an Independent Director of AdvanDx, Inc
Mar 27 13
AdvanDx, Inc. announced that Heiner Dreismann has joined its board of directors as an independent director. Dr. Dreismann has had a distinguished career in the diagnostics industry, both as a senior operating executive and as a director of both public and private companies. Dr. Dreismann was an executive at the Roche group from 1985 to 2006, where he held several senior positions, including President and CEO of Roche Molecular Systems and a member of Roche's Global Diagnostic Executive Committee. Dr. Dreismann currently serves as a director on the board of directors of several public and private health care and diagnostic companies, including Myriad Genetics, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|